Die Osteoporose ist als häufigste Knochenerkrankung im Alter die Ursache vieler Beeinträchtigungen. Definiert wird sie über die Knochendichte, die unter anderem mit der peripheren quantitativen Computertomographie (pQCT) bestimmt werden kann. Mit unseren Daten aus Knochendichtemessungen per pQCT am distalen Radius (XCT 2000) und an der distalen Tibia (XCT 3000) konnten wir im Tukey-HSD-Test zeigen, dass die Knochendichteparameter an oberer und unterer Extremität gut miteinander korrelieren. Es wurden die trabekuläre und die totale Dichte sowie der polare stress-and-strain-Index berücksichtigt. Die trabekuläre Knochendichte an der Tibia, dem gewichtstragenden Knochen, ist höher als die am Radius. Einflussnahme auf die Knochendichte konnte mittels Regressionsanalyse für das Alter, das Geschlecht, die Größe, das Gewicht und den BMI nachgewiesen werden. Die altersbedingte Abnahme der Knochendichte ist an der Tibia stärker ausgeprägt als am Radius. Bei der Frau bedingt eine hohe totale Dichte am Radius eine höhere Festigkeit an der Tibia als bei entsprechenden Dichtewerten beim Mann. Unter Mitberücksichtigung des Alters steigt die Festigkeit an der Tibia beim Mann mit den Jahren an. Bei der Frau sinkt sie, wie auch am Radius, mit steigendem Alter. Das Gewicht nimmt signifikanten Einfluss auf die untere Extremität, nicht jedoch auf den Radius. Die Betrachtung des BMI zeigt, dass nicht die reine Gewichtszunahme sondern die Kombination aus Größe und Gewicht diesen positiven Effekt erzielen, Fettleibigkeit ab dem Adipositasgrad aber einen negativen Einfluss auf die Knochendichte und -festigkeit hat. / As a common bone disease in elderly patients osteoporosis is a cause of severe physical impairment. It is defined by bone mineral density (BMD), which can be determined by peripheral quantitative computer tomography (pQCT). Our data from BMD measurements made by pQCT at the distal radius (XCT 2000) and at the distal tibia (XCT 3000) shows through application of the Tukey-HSD-tests that BMD values at the upper and lower extremities correlate with each other. Total and trabecular BMD as well as the polar stress-and-strain index are considered. Trabecular BMD at the body weight bearing distal tibia is higher than at the distal radius. Influence on BMD was verified by regression analysis for age, sex, height, weight and BMI. Age-related decrease of BMD is more distinct at the tibia than at the radius. In women high total BMD accounts for higher strength at the tibia than it does for corresponding values in men. Considering age, strength of the tibia increases in men during the years. In women it decreases, like it does at the radius. Weight has significant influence on the lower extremity, however not on the radius. Regarding the BMI, not just an increase in mass but a combination of weight and height causes this positive effect. Obesity above level I has a negative influence on BMD and bone strength.

Cement has been selected for wastes immobilization as a simple, low temperature and low cost process for decades. The mechanical and immobilization properties of cement are mainly decided by cement hydration process, especially in the first 24 hours. Previous methods for studying the cement hydration are those include isothermal calorimetry, continuous monitoring of chemical shrinkage, in situ quantitative X-ray diffraction, nuclear magnetic resonance spectroscopy (NMR), quasi-elastic neutron scattering (QENS) and small angle neutron scattering (SANS). Few available in-situ imaging methods were successfully used for net rate study of cement hydration. In this Ph.D. research, innovative imaging techniques such as X-ray computed tomography (XCT) combined with 2D SEM-BSD analysis were combined to study the microstructure and phase change of cement or cement & SrCl2 mixture during hydration. Digital Volume Correlation (DVC) and Digital Image Correlation (DIC) were applied to study the chemical volume shrinkageand drying shrinkage of cement samples during hydration. The effects of SrCl2 simulating the radioactive nuclide from nuclear waste on cement hydration were studied by XRD and ICP-AES techniques. These studies verified that the hydration net rate could be characterised by XCT imaging techniques and the volume shrinkage of cement or cement& SrCl2 mixture during hydration could be characterised by the DVC and DIC techniques.

Glioblastoma Multiforme (GBM) is the most common and malignant form of adult brain cancer, with 95% of patients succumbing to the disease within 5 years of diagnosis. An important contributing factor to this poor prognosis is upregulation of the transmembrane protein system xc- (SXC) found on GBM cells. Approximately 50% of GBM patients have tumors with upregulated levels of SXC, and these patients experience faster disease progression than patients with tumors expressing moderate levels of SXC. SXC is a sodium-independent antiporter and is comprised of a light chain catalytic subunit (xCT) bound to a heavy chain regulatory subunit (4f2hc/CD98) via a disulfide bond. The xCT subunit is responsible for the equimolar exchange of extracellular cystine for intracellular glutamate. Clinical studies have shown areas immediately surrounding the tumor, known as the peritumoral region, reach glutamate concentrations over 100 times that of the normal brain, creating an excitotoxic environment in which neurons cannot survive. In addition to neuronal excitotoxicity, excess glutamate release has also been shown to promote GBM cell invasion, as well as contributing to the clinical presentation of seizures in patients. Moreover, cystine is a component of the antioxidant glutathione, which confers protection to the cells from alkylating therapeutics such as temozolomide (TMZ). In an effort to identify novel targets that regulate SXC function, I investigated the relationship between SXC and two signaling molecules known to promote GBM progression: CD44 and the epidermal growth factor receptor (EGFR). I experimentally manipulated the CD44-hyaluronic acid (HA) interaction and EGFR to determine if these two signaling molecules were involved in regulating SXC expression and function in two patient-derived GBM cell lines. Experimental data led me to conclude that the tumorigenic potential conferred to GBM cells by CD44 is not related to an interaction with SXC. However, I found that knocking down EGFR led to a significant reduction in SXC expression. These findings are important to the field, as combinatorial therapies become more actively pursued in clinical trials. Inhibition of EGFR may provide quality of life benefits to patients who suffer from tumor-associated epilepsy through downregulating xCT-mediated glutamate release. / Doctor of Philosophy / Glioblastoma multiforme (GBM) is an advanced and aggressive form of brain cancer. Incidence of this disease in the United States of America is approximately 3.19 per 100,000 individuals, which translates to more than 13,000 expected annual diagnoses. These tumors arise from genetic mutations that instruct cells to replicate and migrate abnormally. Despite an aggressive medical armamentarium that includes maximal surgical resection, chemotherapy, and radiation, GBM patients have an expected survival period of 12-15 months after diagnosis. Previous studies have shown that approximately 50% of GBM patients have unusually high expression levels of the System xc- (SXC) protein. SXC is a protein transporter located at the membrane of GBM cells, and facilitates the exchange of the excitatory neurotransmitter glutamate for the amino acid dimer cystine. SXC exports glutamate out of the tumor cell, where it can then bind to glutamate receptors on surrounding neurons. In the brain, the concentration of extracellular glutamate must be tightly regulated to prevent hyperexcitability of neurons, which may lead to cell death and the induction of seizures. In patients whose tumors highly express SXC, studies have shown that glutamate levels can rise to concentrations over 100 times greater than the levels seen in normal brain tissue. Additionally, glutamate has been shown to stimulate GBM cells to migrate within the brain and establish secondary tumor sites. The medical and scientific community is justifiably interested in discovering novel methods for regulating or inhibiting SXC-mediated glutamate release. While SXC inhibitors have been identified, clinical studies have determined they are not appropriate for the clinical treatment of GBM. Thus the focus of this project was to identify novel molecular regulators of SXC. To that end, I explored two signaling molecules that are known to promote GBM pathogenesis: CD44 and the epidermal growth factor receptor (EGFR). I found no evidence to support a role for CD44 in regulating SXC in GBM. However, I was able to determine, through genetic and pharmacologic manipulation of patient-derived GBM cells, that EGFR regulates SXC expression and function. The results of these experiments confirmed EGFR as a key signaling protein involved in orchestrating SXC-mediated glutamate release, and may inform future clinical studies investigating combinatorial therapies for GBM patients.

No description available.

京都大学 / 新制・課程博士 / 博士(薬学) / 甲第23843号 / 薬博第850号 / 新制||薬||242(附属図書館) / 京都大学大学院薬学研究科薬学専攻 / (主査)教授 木村 郁夫, 教授 中山 和久, 教授 伊藤 貴浩 / 学位規則第4条第1項該当 / Doctor of Pharmaceutical Sciences / Kyoto University / DFAM

No description available.

Cancer cells adapt to high levels of oxidative stress in order to survive and proliferate, making the transcription factors involved in antioxidant defence regulation targets of interest. The transcription factor NF E2 Related Factor 2 (NRF-2) regulates cellular defence genes including those encoding intracellular redox-balancing proteins such as enzymes involved in glutathione metabolism. Glutathione in particular is an important intracellular antioxidant molecule. NRF-2 binds to the Antioxidant Response Element (ARE) in the promoter of its target genes. Under basal conditions, Kelch-like ECH-associated protein 1 (KEAP1) acts as an inhibitor that targets NRF-2 for ubiquitination. During oxidative stress, NRF-2 dissociates from KEAP1 and enters the nucleus to bind to the ARE sequence. It is hypothesized that the elevated Reactive Oxygen Species may be depleting the glutathione levels within the cancer cell. System xc- is a cystine/glutamate antiporter that exports glutamate while importing cystine to synthesize glutathione. In response to oxidative stress, the cells increase system xc- activity in order to provide cystine for glutathione synthesis. There is evidence that expression of xCT, the specific subunit of system xc-,is regulated by NRF-2. However this has not yet been demonstrated in human breast cancer cells, which is the focus of this project. Basal expression of NRF-2, KEAP1 and xCT was characterized in three breast cancer cell lines (MDA-MB-231, MCF-7 and T47D) and compared to two non-cancer cell lines (184B5 and MCF10A). Basal protein levels of NRF-2 and KEAP1 showed no differences between cell lines. Basal protein levels of xCT were increased in MCF10A cells than T47D cells. MCF-7 cells were treated with hydrogen peroxide (H2O2) resulting in NRF-2 protein accumulation in the nucleus. With H2O2 treatment, xCT mRNA levels increased in MCF-7 cells. Additionally, transient overexpression of NRF-2 increased extracellular glutamate levels in MCF-7 cells. These data support a model that under oxidative stress, NRF-2 is localized to the nucleus and transcriptionally upregulates xCT. This is the first study in which the regulation of xCT has been linked to oxidative stress via NRF-2 in human breast cancer cells. / Thesis / Master of Science (MSc)

No description available.

No description available.

Selenium is a micronutrient that is used by the selenocysteine biosynthesis pathway to produce the amino acid selenocysteine, which is required in selenoproteins. Many of the 25 human selenoproteins, such as glutathione peroxidases and thioredoxin reductases, play important roles in maintaining cellular redox homeostasis. In this study we characterize how this metabolic pathway is upregulated in cancer cells and how this increase in activity creates a unique vulnerability. We have outlined the evidence and underlying mechanisms for how many metabolites normally produced in cells are highly toxic, and we describe this concept as illustrated in selenocysteine metabolism. My thesis explores how SEPHS2, an enzyme in the selenocysteine biosynthesis pathway, is essential for survival of cancer, but not normal cells. SEPHS2 is required in cancer cells to detoxify selenide, an intermediate that is formed during selenocysteine biosynthesis. Breast and other cancer cells are selenophilic, owing to a secondary function of the cystine/glutamate antiporter SLC7A11 that promotes selenium uptake and selenocysteine biosynthesis, which, by allowing production of selenoproteins such as GPX4, protects cells against ferroptosis. However, this activity also becomes a liability for cancer cells because selenide is poisonous and must be processed by SEPHS2. These results show that SEPHS2 is a cancer specific target and indicates the therapeutic potential of SEPHS2 inhibition in the treatment of cancer. Collectively, this thesis identifies SEPHS2 as a targetable vulnerability of cancer cells, defines the role of selenium metabolism in cancer, and outlines a roadmap for future studies regarding toxic metabolites and cancer.